These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34072442)

  • 1. miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer.
    Martini S; Zuco V; Tortoreto M; Percio S; Campi E; El Bezawy R; Doldi V; Landesman Y; Pennati M; Zaffaroni N
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34072442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
    Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
    Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
    Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
    Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
    Marijon H; Gery S; Chang H; Landesman Y; Shacham S; Lee DH; de Gramont A; Koeffler HP
    Oncotarget; 2021 Aug; 12(18):1749-1762. PubMed ID: 34504648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
    Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
    J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 7. PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    Huang X; Xie X; Wang H; Xiao X; Yang L; Tian Z; Guo X; Zhang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 Sep; 36(1):129. PubMed ID: 28915924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
    Martini S; Figini M; Croce A; Frigerio B; Pennati M; Gianni AM; De Marco C; Daidone MG; Argueta C; Landesman Y; Zaffaroni N; Satta A
    Cells; 2020 Oct; 9(10):. PubMed ID: 33023194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 10. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
    Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
    Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanodiamond-based layer-by-layer nanohybrids mediate targeted delivery of miR-34a for triple negative breast cancer therapy.
    Xia Y; Deng X; Cao M; Liu S; Zhang X; Xiao X; Shen S; Hu Q; Sheng W
    RSC Adv; 2018 Apr; 8(25):13789-13797. PubMed ID: 35539318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
    He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
    J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a Enhances the Susceptibility of Gastric Cancer to Platycodin D by Targeting Survivin.
    Peng Y; Fan JY; Xiong J; Lou Y; Zhu Y
    Pathobiology; 2019; 86(5-6):296-305. PubMed ID: 31711057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells.
    Yang B; Huang J; Liu H; Guo W; Li G
    Tumour Biol; 2016 Feb; 37(2):1771-9. PubMed ID: 26318298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Regulation of miR-34a and Notch Signaling in Triple-Negative Breast Cancer by Antibody/miRNA Nanocarriers.
    Valcourt DM; Day ES
    Mol Ther Nucleic Acids; 2020 Sep; 21():290-298. PubMed ID: 32622330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.
    Soung YH; Kashyap T; Nguyen T; Yadav G; Chang H; Landesman Y; Chung J
    Oncotarget; 2017 Aug; 8(32):52935-52947. PubMed ID: 28881784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.